<DOC>
	<DOCNO>NCT00224042</DOCNO>
	<brief_summary>This study compare effect Ferrlecit® ( form intravenous iron ) ferrous sulfate ( form oral iron ) treat anemia iron deficiency chronic kidney disease patient receive erythropoietic agent , Procrit® Aranesp® .</brief_summary>
	<brief_title>Effect Ferrlecit® Versus Oral Iron Iron Deficient Chronic Kidney Disease ( CKD ) Patients Receiving Erythropoietic Agents</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Moderate severe anemia Iron deficiency Moderate severe chronic kidney disease Receiving therapy erythropoietic agent Receiving dialysis Known sensitivity Ferrlecit® component Clinically unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Erythropoietic agent</keyword>
	<keyword>Sodium Ferric Gluconate</keyword>
	<keyword>Anemia , Iron-Deficiency/drug therapy/etiology</keyword>
	<keyword>Kidney Failure , Chronic/blood/complications/therapy</keyword>
	<keyword>Erythropoietin , Recombinant/adverse effects/therapeutic use</keyword>
</DOC>